ACC 2020 The SPYRAL HTN-OFF MED Pivotal Trial showed that renal denervation lowers 24h SBP and office SBP compared to sham control in hypertensive patients in absence of medications.
ACC 2020 The REDUCE-IT EPA study suggests that EPA levels are the predominant driver of CV benefit observed in the REDUCE-IT trial and showed that high EPA levels are associated with a reduced risk of a variety of CV events.
ACC 2020 A sub-analysis of the REDUCE-IT trial, evaluating the effect of icosapent ethyl, showed that higher on-treatment levels of EPA were associated with a reduced risk in CV events.
ACC 2020 An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.
ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.
ACC 2020 Prof. Eisenberg explains the design of the trial with 3 randomisation arms and shares the efficacy and safety findings of e-cigarettes in this short-term trial of 12 weeks.
An initiative of cardiologists and the Dutch CardioVascular Alliance has resulted in the start of the CAPACITY COVID registry, to collect CV data of COVID-19 patients. The initiators call to join now!
The phase III DAPA-CKD trial evaluating the effectivity of SGLT2 inhibitor dapagliflozin in patients with CKD will be stopped early due to overwhelming benefit.
ACC 2020 This study showed that the angiopoietin-like protein 3 inhibitor evinacumab substantially reduces LDL-c in patients with homozygous Familial Hypercholesterolemia (HoFH), regardless of LDL receptor function.
ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.
Prof. Asselbergs calls to participate in the CAPACITY COVID-19 registry, a CV supplement to the existing ISARIC and WHO registry, to collect information on CV variables during the COVID-19 pandemic.
ACC 2020 Oral anticoagulant monotherapy reduced bleeding compared to anticoagulant therapy plus clopidogrel, without increasing ischemic events in AF patients undergoing TAVI.